SCHEMBL15112005

SCHEMBL15112005

CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)Cc1cc(C)no1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ VHL P40337 17/20 1.00
▸ ELOC Q15369 4/20 0.61
▸ ELOB Q15370 4/20 0.61
▸ P2RX7 Q99572 1/20 0.39
▸ EPHX2 P34913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21696710 1.00 VHL (1.00) VHLELOCELOBP2RX7EPHX2
SCHEMBL15110241 0.87 VHL (0.77) VHLELOCELOBP2RX7EPHX2
SCHEMBL15110182 0.87 VHL (0.77) VHLELOCELOBP2RX7EPHX2
SCHEMBL16277194 0.86 VHL (0.76) VHLELOCELOBP2RX7EPHX2
SCHEMBL15125912 0.86 VHL (0.76) VHLELOCELOBP2RX7EPHX2
SCHEMBL15126365 0.84 VHL (0.76) VHLELOCELOB
SCHEMBL16266986 0.84 VHL (0.82) VHLELOCELOB
SCHEMBL15126142 0.84 VHL (0.82) VHLELOCELOB
SCHEMBL15125921 0.83 VHL (0.70) VHLELOCELOBEPHX2
SCHEMBL15125917 0.83 VHL (0.75) VHLELOCELOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317729-A1 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-09-26 — — US disclosed
US-10730862-B2 Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase YALE UNIVERSITY (US) 2020-08-04 — — US disclosed
US-10730862-B2 Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase YALE UNIVERSITY (US) 2020-08-04 — — US disclosed
EP-3608317-A1 COMPOUNDS & METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS & OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE Yale University (US) 2020-02-12 — — EP disclosed
EP-3608317-A1 COMPOUNDS & METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS & OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE Yale University (US) 2020-02-12 — — EP disclosed
US-20190127359-A1 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase UNIV YALE (US) 2019-05-02 — — US disclosed
US-20190127359-A1 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase UNIV YALE (US) 2019-05-02 — — US disclosed
US-20140356322-A1 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2014-12-04 — — US disclosed
US-20140356322-A1 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2014-12-04 — — US disclosed
US-20140356322-A1 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2014-12-04 — — US disclosed
EP-2802608-A2 COMPOUNDS&METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS&OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE Yale University (US) 2014-11-19 — — EP disclosed
WO-2013106643-A2 COMPOUNDS & METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS & OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE YALE UNIVERSITY (US) 2013-07-18 — — WO disclosed
WO-2013106646-A2 COMPOUNDS AND METHODS FOR THE INHIBITION OF VCB E3 UBIQUITIN LIGASE YALE UNIVERSITY (US) 2013-07-18 — — WO disclosed
WO-2013106643-A2 COMPOUNDS & METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS & OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE YALE UNIVERSITY (US) 2013-07-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10730862-B2 Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase VHL, MDM2, NEDD4 VHL 1/4885ELOC 185/4885ELOB 209/4885
US-20140356322-A1 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase VHL, MDM2, STUB1 VHL 1/4885ELOC 190/4885ELOB 241/4885
US-20190127359-A1 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase MDM2, VHL, XIAP VHL 2/4885ELOC 211/4885ELOB 249/4885
US-20240317729-A1 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase MDM2, VHL, XIAP VHL 2/4885ELOC 211/4885ELOB 249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback